Nicolas Robillard

Core open science practices in major medical journals: development of an automatized tool based on a Large Language Model

Constant Vinatier, Guillaume Freyermuth, Margaux Millour, Gauthieu Le Bartz Lyan et autres

Background Open science practices are increasingly promoted to improve the transparency and reproducibility of biomedical research, and their large-scale monitoring has been identified as a priority by initiatives such as the UNESCO Recommendation on Open Science. Existing automated tools cover only narrow …

fr (code pays fourni par la source)

OS-067 Is undetectability of HDV RNA for 96 weeks on Bulevirtide associated with a sustained virological response off-treatment in the real life? Results from the French ANRS HD EP01 HEPDELTA cohort

Helene Fontaine, Marc Bourliere, Miroslava Subic-Levrero, Caroline Jézequel et autres

TRANSLACOL project: Nodal human papillomavirus tumoral DNA detection by ddPCR for survival prediction in early cervical cancer patients without pelvic lymph node invasion

Rosa Montero Macias, David L. Veyer, Thomas Bruneau, Nicolas Robillard et autres

es, fr, ch (code pays fourni par la source)

HPV Molecular Genotyping as a Differential Diagnosis Tool in Cervical Cancer Metastasis

Rosa Montero Macias, Pluvio Coronado, Nicolas Robillard, David L. Veyer et autres

Background: Differentiating metastatic cervical cancer from another primary tumor can be difficult in patients with a history of cervical cancer and a distant lesion. The use of routine HPV molecular detection and genotyping tests could help in these cases. The objective of …

es, fr (code pays fourni par la source)

2022-RA-1480-ESGO TRANSLACOL project: digital-PCR human papilloma virus (HPV) detection for recurrence prediction in early cervical cancer patients without pelvic lymph node invasion

Rosa Montero Macias, Nicolas Robillard, Thomas Bruneau, Coronado Pluvio et autres

fr, es, ch (code pays fourni par la source)

Fusogenicity and neutralization sensitivity of the SARS-CoV-2 Delta sublineage AY.4.2

Nell Saunders, Delphine Planas, William Bolland, Christophe Rodriguez et autres

BACKGROUND: SARS-CoV-2 lineages are continuously evolving. As of December 2021, the AY.4.2 Delta sub-lineage represented 20 % of sequenced strains in the UK and had been detected in dozens of countries. It has since then been supplanted by Omicron. The AY.4.2 spike …

fr (code pays fourni par la source)

Severe relapse of SARS-CoV-2 infection in a kidney transplant recipient with negative nasopharyngeal SARS-CoV-2 RT-PCR after rituximab

Antoine Morel, Sandrine Imbeaud, Anne Scemla, Hélène Péré et autres

Immunocompromised patients may experience prolonged viral shedding after their initial SARS-CoV-2 infection, however, symptomatic relapses after remission currently remain rare. We herein describe a severe COVID-19 relapse case of a kidney transplant recipient (KTR) following rituximab therapy, 3 months after a moderate …

fr (code pays fourni par la source)

Fusogenicity and neutralization sensitivity of the SARS-CoV-2 Delta sublineage AY.4.2

Nell Saunders, Delphine Planas, William Bolland, Christophe Rodriguez et autres

Abstract SARS-CoV-2 lineages are continuously evolving. As of December 2021, the AY.4.2 Delta sub-lineage represented 20 % of sequenced strains in UK and has been detected in dozens of countries. It has since then been supplanted by the Omicron variant. AY.4.2 displays …

fr (code pays fourni par la source)

Circulating Ubiquitous RNA, A Highly Predictive and Prognostic Biomarker in Hospitalized Coronavirus Disease 2019 (COVID-19) Patients

Thomas Bruneau, Maxime Wack, Geoffroy Poulet, Nicolas Robillard et autres

BACKGROUND: Approximately 15-30% of hospitalized coronavirus disease 2019 (COVID-19) patients develop acute respiratory distress syndrome, systemic tissue injury, and/or multi-organ failure leading to death in around 45% of cases. There is a clear need for biomarkers that quantify tissue injury, predict clinical …

fr (code pays fourni par la source)

Release of infectious virus and cytokines in nasopharyngeal swabs from individuals infected with non-alpha or alpha SARS-CoV-2 variants: an observational retrospective study

Blandine Monel, Delphine Planas, Ludivine Grzelak, Nikaïa Smith et autres

BACKGROUND: The dynamics of SARS-CoV-2 alpha variant shedding and immune responses at the nasal mucosa remain poorly characterised. METHODS: We measured infectious viral release, antibodies and cytokines in 426 PCR+ nasopharyngeal swabs from individuals harboring non-alpha or alpha variants. FINDINGS: infectious units. …

fr (code pays fourni par la source)

Persistent Coronavirus Disease 2019 (COVID-19) in an Immunocompromised Host Treated by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)-Specific Monoclonal Antibodies

B. Bailly, Hélène Péré, David L. Veyer, Ana Berceanu et autres

To the Editor—We read with interest the article from John Paul Verderese et al about the efficacy of neutralizing monoclonal antibody (NmAb) in patients with mild or moderate coronavirus disease 2019 (COVID-19) infection in order to prevent hospitalization [1]. We suppose that …

fr, us (code pays fourni par la source)

Transmission of SARS-CoV-2 Alpha Variant (B.1.1.7) From a BNT162b2-Vaccinated Individual

Solen Kernéis, Delphine Planas, Sandrine Imbeaud, Isabelle Staropoli et autres

Cases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) acquisition after vaccination with BNT162b2 have been described, but the risk of secondary transmission from fully vaccinated individuals remains ill defined. Herein we report a confirmed transmission of SARS-CoV-2 alpha variant (B.1.1.7) from …

fr (code pays fourni par la source)